Anemia Management in Dialysis Patients Flashcards

According to KDIGO guidelines, what is the target hemoglobin range for dialysis patients receiving erythropoiesis-stimulating agent (ESA) therapy?

Answer: 10–11.5 g/dL

KDIGO guidelines recommend maintaining hemoglobin between 10–11.5 g/dL in dialysis patients on ESA therapy to balance symptom relief while minimizing cardiovascular risks.

What is the primary cause of anemia in patients with chronic kidney disease (CKD)?

Answer: Decreased erythropoietin production by damaged kidneys

The diseased kidneys produce insufficient erythropoietin (EPO), the hormone that stimulates bone marrow red blood cell production, making EPO deficiency the principal cause of CKD anemia.

Which laboratory value best reflects total iron stores in dialysis patients when assessing for iron deficiency?

Answer: Serum ferritin

Serum ferritin is an acute-phase protein that reflects total body iron stores and is the most reliable single marker used to assess iron adequacy in dialysis patients.

What transferrin saturation (TSAT) level is considered indicative of iron deficiency requiring supplementation in hemodialysis patients?

Answer: Less than 20%

A TSAT below 20% indicates insufficient circulating iron available for erythropoiesis and is a key threshold for initiating iron supplementation in hemodialysis patients.

A hemodialysis patient has a hemoglobin of 8.4 g/dL, serum ferritin of 140 ng/mL, and TSAT of 17%. Which intervention is most appropriate?

Answer: Administer intravenous (IV) iron supplementation

With TSAT <20% and ferritin <200 ng/mL, this patient has iron deficiency anemia; IV iron is preferred over oral iron in hemodialysis patients due to superior absorption and avoidance of GI side effects.

Which erythropoiesis-stimulating agent (ESA) has a significantly longer half-life than epoetin alfa, allowing for less frequent dosing?

Answer: Darbepoetin alfa

Darbepoetin alfa (Aranesp) has a half-life approximately three times longer than epoetin alfa due to additional sialic acid residues, allowing weekly or biweekly dosing instead of three times per week.

At what hemoglobin level should a dialysis nurse notify the provider to consider reducing or holding the ESA dose to avoid adverse outcomes?

Answer: Greater than 12 g/dL

ESA dose should be reduced or held when hemoglobin exceeds 12 g/dL in dialysis patients, as higher levels are associated with increased cardiovascular events and stroke risk per FDA labeling.